Megan Wood, MD
Endocrinology, Diabetes & Metabolism · St. Louis, MONPI 1407052996
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $147,160 of the $206,860 with a category attached, or 71.1%. Corcept Therapeutics accounts for 91.4% of it on its own, with 45 other manufacturers making up the rest. 2025 is the largest year on record at $124,942, more than ten times the $2,103 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,249 payments — averaging $165.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$189K
- Insulet Corporation$4K
- Novo Nordisk$3K
- AstraZeneca$2K
- Xeris Pharmaceuticals, Inc.$1K
- Abbott$1K
- plus $7K from 40 others
What the payments were for
- Consulting fees$5,8403%
- Speaking & faculty fees$147,16071%
- Travel & lodging$34,21117%
- Food & beverage$19,5329%
- Education$570%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,860 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 44 | $1,775,175 |
| OzempicSemaglutide | 113 | $176,167 |
| MounjaroTirzepatide | 60 | $96,469 |
| FarxigaDapagliflozin Propanediol | 86 | $91,460 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $55,832 |
| TrulicityDulaglutide | 21 | $31,404 |
| JardianceEmpagliflozin | 23 | $30,399 |
| JanuviaSitagliptin Phosphate | 29 | $28,230 |
| Bydureon BciseExenatide Microspheres | 11 | $26,738 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 12 | $23,027 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $14,715 |
| XyostedTestosterone Enanthate | 16 | $9,329 |
| Repatha SureclickEvolocumab | 11 | $8,629 |
| HumalogInsulin Lispro | 20 | $5,000 |
| SynthroidLevothyroxine Sodium | 41 | $4,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $189,173 | $1,775,17544 claims |
| Novo NordiskOzempic | $3,012 | $176,167113 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $661 | $132,873101 claims |
| AstraZenecaFarxiga | $2,047 | $91,46086 claims |
| Boehringer IngelheimJardiance | $249 | $30,39923 claims |
| MerckJanuvia | $130 | $28,23029 claims |
| Antares Pharma, Inc.Xyosted | $420 | $9,32916 claims |
| AbbVieSynthroid | $857 | $4,04541 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $346 | $3,695140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in St. Louis
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
- Adam MaghrabiBlue Springs$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.